Chi Sheng Pharma & Biotech Co., Ltd.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. carries a market capitalization of 1.79B, placing it among publicly traded companies globally. Its enterprise value stands at 1.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chi Sheng Pharma & Biotech Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. has 59.83M shares outstanding.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. trades at a trailing price-to-earnings ratio of 9.50. The price-to-sales ratio is 1.26, and the price-to-book ratio stands at 1.28.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. trades at an EV/EBITDA multiple of 4.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Chi Sheng Pharma & Biotech Co., Ltd. trades at an EV/FCF ratio of 6.20, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.36B versus a market cap of 1.79B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.21, indicating elevated leverage, while an interest coverage ratio of 605.18 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. posted a return on equity (ROE) of 14.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.93 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.24, useful for judging operating efficiency across full business cycles. The company generates approximately 4.99M in revenue per employee across its workforce of 285.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.69 indicates how many times Chi Sheng Pharma & Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. recorded 53.81M in income tax expense. That works out to an effective tax rate of 22.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 242.87M, leaving 189.07M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Chi Sheng Pharma & Biotech Co., Ltd.'s stock has declined approximately 5.75% over the past 52 weeks. The 50-day moving average sits at 29.04, while the 200-day moving average is 29.58.

Over the twelve months ended June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. generated 1.42B in revenue and converted that into 189.07M in net income, yielding earnings per share of 3.13. EBITDA reached 275.96M, while operating income came in at 204.11M.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. holds 472.29M in cash and equivalents against 44.98M in total debt, resulting in a net debt position of -435.92M. Total book value stands at 1.40B, with working capital of 434.37M providing operational flexibility.

Chi Sheng Pharma & Biotech Co., Ltd. produced 306.83M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -86.94M in capital expenditures, free cash flow totaled 219.89M - equivalent to 3.67 per share.

Over the twelve months ended June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. posted a gross margin of 39.39, reflecting its pricing power and cost economics. The operating margin of 14.36 and net profit margin of 13.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 12.16, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chi Sheng Pharma & Biotech Co., Ltd. shareholders.

Chi Sheng Pharma & Biotech Co., Ltd.'s most recent stock split took place on August 26, 2025 with a 20:21 split ratio.

As of June 30, 2026, Chi Sheng Pharma & Biotech Co., Ltd. has an Altman Z-Score of 3.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.